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ABSTRACT
Background: Catheter-related bloodstream infection (CRBSI) is
a life-threatening complication of parenteral nutrition. Therefore,
optimal management, ideally with catheter salvage, is required to
maintain long-term venous access.
Objectives: We aimed to evaluate successful catheter salvage rates
in patients on home parenteral nutrition (HPN).
Methods: Studies were retrieved from medical databases, confer-
ence proceedings, and article reference lists. Data were collected
relating to clinical outcomes of 3 treatments: systemic antibiotics,
antimicrobial lock therapy (ALT), and catheter exchange. ORs and
95% CIs were calculated from a mixed logistic effects model.
Results: From 10,036 identified publications, 28 met the inclusion
criteria (22 cohort studies, 5 case-control studies, and 1 randomized
clinical trial), resulting in a total of 4911 CRBSIs. To achieve
successful catheter salvage, the addition of an antimicrobial lock
solution was superior to systemic antibiotics alone (OR: 1.75;
95% CI: 1.21, 2.53; P = 0.003). Recurrence of infection was less
common in studies that used ALT than in those that used systemic
antibiotics alone (OR: 0.26; 95% CI: 0.11, 0.61; P = 0.002). The
catheter exchange group was excluded from multilevel regression
analysis because only 1 included study applied this treatment.
Successful salvage rates were highest for coagulase-negative
staphylococci, followed by Gram-negative rods and Staphylococcus
aureus .
Conclusions: The addition of an antimicrobial lock solution
seems beneficial for successful catheter salvage in HPN-dependent
patients with a CRBSI. Future prospective randomized studies
should identify the most effective and pathogen-specific strategy.
This review was registered at www.crd.york.ac.uk/PROSPERO as
CRD42018102959. Am J Clin Nutr 2021;114:1173–1188.
Keywords: home parenteral nutrition, catheter-related bloodstream
infection, antimicrobial lock solution, catheter salvage, catheter
exchange, antimicrobial therapy
Introduction
Catheter-related bloodstream infection (CRBSI) is a frequent
and life-threatening complication in patients receiving home
parenteral nutrition (HPN). HPN is a life-sustaining therapy
in patients who suffer from intestinal failure (IF) and hence
cannot meet their nutritional and/or fluid requirements by enteral
intake owing to underlying conditions that limit gastrointestinal
absorption (1). HPN is administered systemically via a central
venous access device, mostly in the form of a central venous
catheter (CVC) or an implantable port. Although HPN is
generally lifesaving in these patients, its use is also associated
with the risk of infectious and noninfectious catheter-related
complications (2). Of these, CRBSI is the most common and
is a potentially life-threatening complication. CRBSIs can lead
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to CVC removal. Multiple CVC removals are associated with
venous stenosis and thrombosis which, in turn, can lead to the
permanent loss of vascular access. When this occurs, the patient
may eventually require a small bowel transplantation (3, 4).
The impact that recurrent CVC removal can have on future
venous access implies that catheter salvage should be attempted
wherever possible in HPN-dependent patients with CRBSI.
Whereas guidelines recommend CVC removal in most cases of
CRBSI, catheter salvage aims to retain the CVC with the use
of appropriate catheter lock therapy and systemic antibiotics,
usually for ≥10–14 d (5, 6). Catheter salvage is attractive because
it obviates the inconveniences and risks of CVC replacement,
especially in those patients who have limited remaining venous
access or who cannot tolerate prolonged periods without HPN
(7). Catheter removal, on the other hand, reduces the risk
of infection recurrence, persistent bacteremia, and metastatic
infection (8–11). However, the appropriateness of catheter
salvage in specific situations remains contentious (5, 6, 12, 13).
Current European HPN guidelines recommend attempting CVC
salvage solely in patients with uncomplicated infections arising
from Staphylococcus aureus, coagulase-negative staphylococci
(CNS), and Gram-negative bacilli (12). The Infectious Diseases
Society of America (IDSA) guidelines advocate catheter removal
or replacement as a first-line approach to CRBSI (5). All
guidelines agree on removing the CVC in patients who are
hemodynamically unstable, for CRBSIs caused by yeasts,
or in cases of complicated infections such as endocarditis,
septic thrombosis, and other metastatic infections (5, 12, 14).
However, the recommended treatment for certain high-virulence
bacteria (e.g., S. aureus and Pseudomonas aeruginosa) remains
controversial. For instance, whereas the IDSA recommends CVC
removal in case of S. aureus and Gram-negative infections (5),
some IF expert centers report high rates of successful catheter
salvage with these bacteria (15–17).
In addition to the indications for CVC salvage, several other
uncertainties exist around CRBSI management. One of these
is the added value of an antimicrobial lock solution next to
conventional systemic antibiotic treatment and another is the
option of guidewire exchange instead of catheter removal;
antimicrobial lock solution consists of high concentrations of
an antimicrobial agent (often combined with an anticoagulant)
instilled into the catheter lumen. Guidewire exchange is a
technique that has previously been reported in studies mainly
concerning hemodialysis patients (18). This technique involves
the insertion of a guidewire through the infected CVC into
the vein, followed by removal of the infected catheter and
placement of a new catheter over the guidewire. However,
the optimal strategy to salvage a catheter remains unclear
owing to the lack of well-designed randomized clinical trials
(RCTs).
Because current guidelines (5, 6, 12, 14, 19) vary in their
recommendations, we conducted, to our knowledge, the first
systematic review to appraise the available evidence on CRBSI
management specifically in adult patients on HPN support, focus-
ing on the safety and efficacy of available CRBSI management
approaches with successful catheter salvage as the outcome.
These data should lead to more consistent recommendations
for CRBSI management between the different international
societies.
Methods
The systematic review and meta-analysis were performed
using the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines (20). For the report
format, we followed the Meta-analysis Of Observational Studies
in Epidemiology (MOOSE) guidelines. Before conducting this
systematic review, the protocol was registered in the International
Prospective Register of Systematic Reviews (PROSPERO)
database (CRD42018102959).
Search strategy
Our research question was: “What is the most efficacious
and safest management approach (intervention) to accomplish
high catheter salvage rates (outcome) in adult patients on
home parenteral nutrition with catheter-related bloodstream
infection (population)?” The following databases were searched
from inception through March 2021: PubMed, Excerpta med-
ica database (Embase), Cochrane library (Cochrane Database
of Systematic Reviews and Cochrane Central Register of
Controlled Trials), Cumulative Index to Nursing and Allied
Health Literature (CINAHL), and Web of Science. The search
strategy was composed by experts in the field and included
the following terms: “parenteral nutrition,” “home infusion,”
“catheter,” and “infection.” Because of the large variety and
interchangeability of terms used for the outcomes of CBRSI
management, we did not incorporate terms related to the
outcome in our search strategy. Supplemental Table 1 displays
the search strategy. We hand-searched conference proceedings
(period: 2000–2020) of European Society for Clinical Nu-
trition and Metabolism (ESPEN) meetings and clinical trial
registries [clinicaltrials.gov, International Standard Randomised
Controlled Trial Number (ISRCTN) register, and Australian New
Zealand Clinical Trials Registry (ANZCTR)] for unpublished
studies, which were considered as gray literature. The reference
lists of all relevant guidelines and reviews were manually
searched to identify additional relevant studies. When needed,
we contacted the authors of the included publications by
e-mail to further clarify their data. We also included studies in
languages other than English and translated these articles into
English.
Study selection
Articles retrieved from the literature search were first dedupli-
cated using filters and export formats, as described by Bramer
et al. (21). The remaining articles were imported into an online
software program (Covidence 2018) to screen the abstracts for
eligibility. Two independent reviewers (MG and CP) screened
the titles and abstracts of the retrieved citations. The full texts
of potentially eligible articles were reviewed to identify relevant
studies for inclusion. Studies were included when they focused
on managing bloodstream infections from central venous access
devices in adult patients receiving HPN.
Inclusion criteria
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2) use of either systemic antibiotics, antimicrobial lock
therapy (ALT), and/or catheter exchange as the CRBSI
management approach;
3) evaluation of treatment efficacy (i.e., successful catheter
salvage, recurrence rates, and/or infectious complications).
Main exclusion criteria
1) Use of ALT for prevention only;
2) use of catheter removal as the sole management approach.
In addition, studies that only involved patients with previous
CRBSI treatment failure or infectious complications were
excluded. Studies incorporating different patient populations
were only included if the text outlined that patients on parenteral
nutrition were included. Studies only containing children were
excluded in order to limit the heterogeneity of the patient
population and because of expected differences in CRBSI
etiology, diagnosis, and management (22, 23). When distinct
publications had partly overlapping data due to the same patients’
inclusion, the results were either combined or collected from
the most extensive study to avoid duplicate data. Selected
studies included interventional clinical trials and case-control and
observational cohort studies.
Outcome measures
The major outcome of interest was successful catheter salvage
rates, with a distinction between:
1) Overall catheter salvage rate = ratio of successfully
salvaged catheters to total CRBSIs.
2) Successful catheter attempt rate = ratio of successful
salvage attempts according to the protocol to total salvage
attempts.
The secondary outcomes comprised recurrence, infectious
complications, mortality, and catheter salvage rates per pathogen
type. The infecting pathogens were divided into 4 microbiologi-
cal categories: CNS, S. aureus, Gram-negative rods (GNR), and
polymicrobial.
Data extraction and risk of bias
Two reviewers (MG and CP) independently extracted data
from each included study relating to patient and venous access
characteristics, CRBSI management approach, microbiological
results, reported outcomes, and follow-up duration. All included
studies were appraised for methodological study quality using
the Newcastle-Ottawa Scale (NOS) for cohort and case-control
studies. This tool covers the evaluation of participant selection,
comparability of groups, and assessment of outcome. The
questions in these domains were adapted to our research topic
(adequate follow-up of ≥30 d, loss to follow-up ≤ 20%, adequacy
of the method to diagnose CRBSI, and risk of bias due to
study design) (Supplemental Figure 1). A maximum of 9 points
could be awarded to each study, with higher points representing
a lower risk of bias. A qualitative assessment determined the
main exclusion criteria for CVC salvage attempts and the
limitations of each study separately (Supplemental Table 2).
Any disagreements on data extraction or bias assessment were
resolved through discussion with experts in the field (GJAW,
CPB-R, SL, AB). None of the quality assessors were blinded.
Study heterogeneity was assessed by the Cochrane Q test
of heterogeneity and I2 statistic. We examined the presence
of publication bias by producing a funnel plot with Egger’s
statistical test of successful catheter salvage as outcome against
study size for each treatment.
Definitions and outcomes
CRBSI definitions.
CRBSI. Based on the IDSA definition: positive blood cultures
from catheter blood drawn from the catheter and a peripheral
vein with a ratio of ≥3:1 (CVC vs. peripheral); and a
differential period of CVC culture versus peripheral blood culture
positivity of 2 h. Alternatively, and as per IDSA guidelines,
a CRBSI was defined when the same organism was grown
from ≥1 percutaneous blood culture and from the catheter tip
(5).
Central line–associated bloodstream infection. This was defined
based on the CDC guidelines (6, 14). At least 1 of the following
criteria should be present: 1) positive blood culture from a
known pathogen, or 2) positive blood cultures from common skin
commensal organisms and symptoms of infection with no other
potential source of infection. Studies with stricter criteria than
central line–associated bloodstream infection (CLABSI), such as
positive blood cultures from both catheter and peripheral vein,
were categorized as CLABSI because they were broad enough to
meet CLABSI criteria but not strict enough to meet the CRBSI
criteria.
No standard criteria. Studies that did not provide a proper
definition or reference to a standard definition for infectious
catheter-related complications were categorized as “no standard
criteria.”
Catheter salvage
1) Catheter salvage rate.
Defined by CVC status (retained or removed), clinical
resolution, and no recurrence within 30 d of the previous CRBSI
date.
2) Overall successful catheter salvage.
Calculation of catheter salvage rates, including all CRBSI
cases (regardless of the reason for removal), according to Tribler
et al. (24).
3) Successful catheter salvage attempt rate.
Calculation of catheter salvage rates, including only attempted
catheter salvage cases according to protocol and/or guidelines.
Recurrence
• Recurrence was defined as any new CRBSI with the same
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FIGURE 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram. The flowchart represents the literature search and elements
of the systematic review (identification, screening, and analysis). CINAHL, Cumulative Index to Nursing and Allied Health Literature; CLABSI, central line–
associated bloodstream infection; CVC, central venous catheter; Embase, Excerpta medica database.
within 30–90 d of the previous CRBSI date. Recurrence data
beyond 90 d were not extracted (unless representing the only
measure of recurrence), because recurrence beyond this
point is considered unlikely to be significantly influenced
by the primary treatment (24, 25).
• New infection was defined as any new CRBSI with a
different microbial species or different antibiograms from
the former infection (24).
Data synthesis and statistical analysis
Studies were divided into 3 treatment groups: 1) systemic
antibiotic treatment only, 2) systemic antibiotics with the
addition of ALT, and 3) CVC exchange. For most observational
cohort studies, a direct comparison of treatments was not
possible. Therefore, study results were synthesized between the
3 treatment groups by comparing the catheter salvage rates
(displayed in proportions) with the treatments considered in that
study (26). A mixed logistic effects model was built with a study-
specific normal random effect that modified the mean log-odds
for successful catheter salvage for the particular treatments. The
treatment groups were included as a fixed effect and a study-
specific random effect that modeled the studies’ heterogeneity.
The differences in salvage rates between the treatments were
evaluated using ORs with 95% CIs, and P values from the Wald
test. For each treatment, each study was weighted by the number
of patients receiving that treatment. The secondary outcomes
were compared using the same methodology as described
for the primary outcome. Heterogeneity was summarized for
each of these outcomes using the χ2 test and I2 statistics
(27). Publication bias was investigated by Egger’s regression
test and funnel plots (28). The Statistical Package for the
Social Sciences (SPSS version 23, IBM Corp.) was used for
the mixed-effects logistics analysis. The R statistical platform
(version 4.0.5, www.r-project.org) was used to generate the forest




The initial search yielded 16,072 articles, but only 289 articles
remained for full-text screening after deduplicating and exclusion
by title and abstract (Figure 1). Five of these articles were found
by screening the reference lists of relevant reviews. After full-text
screening, 28 studies met the inclusion criteria for meta-analysis,
representing 4911 CRBSIs (range: 8–1441) (15–17, 24, 31–54).
All studies were published between 1981 and 2020. In addition,
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suitable for a narrative review. Supplemental Tables 3 and 4
summarize the list of included and most important excluded
studies, including reasons for exclusion.
Description of the studies
The majority of the 28 included studies were conducted in
Europe (n = 21) (15, 16, 24, 31–34, 36–39, 41–45, 48, 50–
53) and the United States (n = 6) (17, 35, 40, 46, 47, 54)
(Supplemental Figure 2). Twenty-five studies were carried out
in tertiary hospitals and/or specialized IF units (15–17, 24, 33–
35, 37–54) and 2 studies were multicenter (31, 32). Twenty-
two studies were conducted as single-arm studies (Tables 1, 2).
The majority of these studies administered ALT in addition
to systemic antibiotic therapy (n = 12) (15–17, 32, 38, 40–
45, 50) as standard care in their CRBSI management, whereas
other studies only used systemic antibiotics (n = 10) (24,
39, 46–49, 51–54). Five studies had a case-control design
(33–37):
• One study compared CVC exchange with catheter retention
and systemic antibiotic therapy (34).
• Two studies compared catheter removal with catheter
retention and either ALT (33) or systemic antibiotics (35).
• Two studies compared systemic antibiotics with ALT (36,
37).
The remaining study was an RCT comparing ALT with
placebo, both in addition to systemic antibiotic therapy (31).
Study duration ranged from 1 to >23 y and the patient follow-
up time ranged from 7 to 540 d. A trend toward more ALT studies
being published in the last decade was apparent (Supplemental
Figure 3).
Patient population
Across all studies, the included patients’ median age was 53 y
(IQR: 48–58 y) (missing = 9) (Tables 1, 2). Nineteen studies only
included patients receiving parenteral nutrition (missing = 4).
The median percentage of females was 50% (IQR: 40%–56%)
(missing = 14). Eleven studies reported the percentage of
oncological patients and 7 of these included >50% oncological
patients (mean ± SD: 67% ± 33%). The mean CRBSI rate
was 1.06 per 1000 CVC days (range: 0.04–2.8 per 1000 CVC
days).
CRBSI and salvage definitions
Most studies defined CRBSIs according to the CDC (17, 35,
39, 43–45, 52) or IDSA (15, 16, 31, 32, 36, 50) guidelines;
the other studies used either nonstandard definitions or did not
report the definition used (33, 34, 37, 41, 48, 49, 51, 53, 54).
Two studies reported a slightly modified definition, but were still
considered as appropriate and were counted as using the CDC
definition (24, 38). Reported salvage rates differed widely among
studies: 9 studies reported overall salvage rates (17, 24, 34, 38, 40,
47, 49, 52, 54), whereas 18 studies reported successful salvage
rates (e.g., exclusion of S. aureus for salvage) (15, 16, 31–33,
35–37, 41, 42–46, 48, 50, 51, 53) (Supplemental Table 2). One
study did not mention the method of salvage (39). There was
a wide variety of defining successful catheter salvage, varying
from solely negative blood cultures after completing antimi-




All single-arm studies except 1 (40) used ALT in combination
with systemic antibiotic treatment. Two case-control studies only
administered systemic antibiotics to a selection of patients in the
control group (33, 37). Antibiotic lock solutions with vancomycin
as an empiric lock solution were used most frequently, which
was later changed according to sensitivity. One study used a
lock containing taurolidine (41). Heparin was frequently added
as an anticoagulant in the lock solution. Dosage, concentration,
and duration of lock solutions varied highly among studies
(Table 3).
Systemic antibiotics.
The type of administered systemic antibiotics varied consider-
ably among studies. Most studies mentioned empirical treatment
according to IDSA guidelines with sensitivity-based adjustments.
Several studies were unclear about administered antibiotics (17,
33–35, 39, 46, 47). Some studies used or reported notable
percentages of inappropriate antibiotic treatments (32, 37)
or administered extended broad-spectrum empirical antibiotic
treatment (44, 48, 49), probably because those studies were
performed in regions with a high prevalence of multiresistant
bacteria.
Catheter exchange.
Only 1 case-control study used CVC exchange as the CRBSI
treatment (34). Because a low number of included studies per
subgroup induces the risk of problems with collinearity, the CVC
exchange group was excluded from the meta-regression subgroup
analysis (55).
Efficacy of different treatment approaches
Successful catheter salvage rates per intervention type could be
determined for 24 studies (15–17, 24, 31, 32, 34–42, 44–47, 49,
51–54). Four studies were excluded from the primary outcome: 2
studies only evaluated salvage rates for CRBSIs caused by CNS
(43, 51) and the other 2 studies used ungeneralizable outcomes
(33, 48). Nineteen studies reported on recurrence rates (15, 16,
24, 31–37, 39–44, 48, 51, 54).
Primary endpoint: successful catheter salvage rates for
CRBSI
Figure 2 reports the results of the studies. Figure 2A shows
a forest plot of pooled successful CVC salvage proportions
for individual studies in each intervention type. The combined
successful CVC salvage rate was 68% (95% CI: 64%, 72%).
Figure 2B displays a subanalysis of studies using systemic
antibiotics alone with a salvage rate of 60% (95% CI: 56%, 64%)
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ALT. A low degree of heterogeneity at 23% (P = 0.21) was
seen in studies that used ALT and a moderate heterogeneity at
61% (P < 0.01) in studies that only used systemic antibiotics.
A sensitivity analysis performed by excluding the 2 studies
(34, 53) having <10 patients did not produce pooled salvage
proportions that differed from those of the main analysis. Mixed-
effects logistic regression analysis showed that the combination
of systemic antibiotics with ALT was superior to systemic
antibiotics alone (OR: 1.75; 95% CI: 1.21, 2.53; P = 0.003).
Additional multilevel regression analysis correcting for NOS
score, follow-up duration, vascular access type, and type of
salvage definition used did not affect these outcomes (adjusted
OR: 1.79; 95% CI: 1.32, 2.43; P < 0.001).
Secondary endpoints
Recurrence rates.
Figure 3 displays a forest plot of recurrence rates (displayed
in proportions) per intervention type. I2 demonstrates moderate–
high heterogeneity at 68% (P < 0.01). Meta-regression analysis
showed that recurrence was less common in studies that used the
addition of ALT (weighted mean: 10%; range: 4%–29%) than
in those that used systemic antibiotics alone (weighted mean:
15%; range: 7%–61%) (OR: 0.26; 95% CI: 0.11, 0.61; P = 0.002)
(CVC exchange group excluded).
Successful salvage rates per pathogen category.
Successful catheter salvage rates per pathogen (divided into
S. aureus, CNS, Gram-negative bacteria, polymicrobial, and
other) were evaluable for 19 studies (15–17, 24, 32, 36, 38–40,
42–44, 46, 47, 50–54) and comprised of 3739 CRBSIs. CNS
represented the majority of isolates (37%, n = 1388), followed
by Gram-negative bacteria (33%, n = 1238) and S. aureus (9%,
n = 340). Of the CRBSIs, 12% were polymicrobial in origin
(n = 448). Supplemental Tables 5 and 6 report absolute numbers
of CRBSIs per pathogen. Successful CVC salvage rates were
compared by type of bacteria and separately per type of treatment
(Figure 4). Weighted mean salvage rates in CNS cases were
highest (75%; range: 68%–95%), followed by Gram-negatives
(56%; range: 33%–92%). CRBSIs caused by S. aureus (54%;
range: 25%–100%) and polymicrobial infections (54%; range:
36%–88%) had the lowest CVC salvage rates. Taking the type
of treatment into account, successful salvage rates of various
bacteria remained different, with the highest success rates for
CNS followed by GNR and S. aureus. The ORs of successful
salvage were as follows: CNS compared with S. aureus: 3.00;
95% CI: 2.33, 3.85; P < 0.001; CNS compared with GNR: 2.19;
95% CI: 1.84, 2.60; P < 0.001; and GNR compared with S.
aureus: 1.37; 95% CI: 1.07, 1.76; P = 0.01. Among S. aureus
and GNR infections, studies that added ALT achieved signif-
icantly higher successful CVC salvage rates than studies that
solely used systemic antibiotics without an antimicrobial lock
(Table 4).
Other outcomes
Seventeen studies (15, 17, 32, 34, 36–39, 41, 42, 45, 47–
52) reported on infectious complications (including infection-
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1%–30%) in the ALT group (11 studies) compared with 12%
(range: 7%–29%) in the systemic antibiotic group (8 studies)
and 5% (range not applicable) in the catheter exchange group
(1 study). Incidence of infectious complication rates did not differ
between the different interventions (P = 0.58) (CVC exchange
group excluded).
Risk of bias
Supplemental Table 7 provides an evaluation of the studies’
quality and details the risk of bias within studies according to
a modified NOS. Most studies had a low risk of bias, whereas
6 studies had a moderate (37, 41, 45, 46, 48) or high risk of bias
(52). The overall median of the total NOS score was 6 out of
9. When the risk of bias was introduced as a covariate in the
model for successful CVC salvage, its effect was not significant
(P = 0.74). The funnel plot showed that successful salvage
rates did not differ between small and large studies that used
ALT in addition to systemic antibiotics as treatment (P = 0.17),
indicating no evidence of publication bias (Figure 5). However,
funnel plot asymmetry was present in studies that used systemic
antibiotics alone, mostly due to the absence of larger studies with
higher salvage rates (P = 0.002).
Narrative review of gray literature (unpublished studies)
and case reports
The majority of unpublished studies on CRBSI treatment in
HPN patients address the efficacy and safety of catheter salvage
by ALT in addition to systemic antibiotic treatment. Haneda
et al. (56) reported a high efficacy of ALT with vancomycin
(25 mg/mL, twice daily for 10–14 d) in 7 HPN patients suffering
from a total of 10 CRBSIs. The treatment success rate was 90%,
although 1 patient developed a recurrent CRBSI within 30 d.
The causative pathogens of the CRBSIs in this study were not
reported. ALT with vancomycin was also successful in 8 of
9 cases of CRBSIs caused by Bacillus cereus, a pathogen for
which the IDSA guidelines would advise catheter removal (57).
A retrospective analysis of the addition of ALT in 10 hemato-
oncological patients (8 received HPN) with a port-infection
revealed a high rate of CVC removal after CRBSI (58). Although
intraluminal treatment with antibiotics was not attempted in all
patients, the CVC was removed in 7 of 10 cases (5 cases of
CNS, 4 cases of Gram-negative bacilli, and 1 case of methicillin-
susceptible S. aureus). Udvarhelyi et al. (59) examined the
catheter retention time during the implementation of their
catheter preservation protocol. The time to catheter replacement
was prolonged by a mean of 118.7 d. Three patients presented
with recurrent CRBSIs, 1 of whom developed endocarditis during
the third recurring CRBSI. This led to the policy of CVC removal
after the occurrence of a second CRBSI. The unpublished study
of Ward et al. (60) found that catheter salvage was more likely
to fail in CRBSIs with S. aureus. Patients were treated with
either systemic antibiotics only or in combination with ALT.
Attempted catheter salvage was successful in 79% of the cases.
The additional use of ALT resulted in similar salvage rates as
intravenous antibiotic therapy alone. Of note, catheter salvage
was not attempted (5 of 29 cases) when additional complications











trecht user on 26 O
ctober 2021
1182 Gompelman et al.
TABLE 3 Type of ALT and comparison treatment per included study1
Study (n = 15), country Lock protocol Lock solution
Comparison
treatment
Bond et al. (16), United
Kingdom
Referred to Dibb et al. (15). Referred to Dibb et al. (15). N/A
Clare et al. (38), United
Kingdom
Duration not stated. Systemic ABs: not
specified.
Sensitivity-guided solutions (not further
specified).
N/A
Dibb et al. (15), United
Kingdom
10 d for CNS; 14 d for all other
pathogens. Systemic ABs:
vancomycin, changed according to
sensitivities if available.
Empirical: 4 mg vancomycin/mL; 5000 IU
urokinase/mL. Changed according to
sensitivities if available.
N/A
Edakkanambeth Varayil et al.
(17), United States
Duration not stated. Systemic ABs:
vancomycin and cefepime (7–14 d).
Empirical: vancomycin lock. N/A
Fernandez-Hidalgo et al. (42),
Spain
Up to 10 d. Systemic ABs: vancomycin
or ciprofloxacin.
GPC: 2 mg vancomycin/mL with 20 IU
heparin/mL;GNR: ciprofloxacin or
amikacin (2 mg/mL) with 20 IU
heparin/mL.
N/A
Fortún et al. (36), Spain Every 3 d and used for 8–12 h/d, for
10–14 d. Systemic ABs (not further
specified).
GPC: 2 mg vancomycin/mL with 20 IU
heparin/mL.GNR: ciprofloxacin or









Guedon et al. (43), France 14 d. Culture-guided systemic ABs (22
of 34 cases).
Empirical: 5 mg teicoplanin/2 mL. N/A
Haag et al. (41), Germany 3–4 d. Culture-guided systemic ABs. Taurolock Hep 100® (1.4%
cyclo-taurolidine, 0.4% citrate solution,
100 IU heparin/mL).
N/A
Krzywda et al. (40), United
States
3 cc of diluent, instilled with dwell time
of 12 h; 5–17 d. No systemic ABs.
Sensitivity-guided solutions (nafcillin:
250–500 mg; erythromycin: 200 mg;
amphotericin: 1 mg; ceftriaxone:
250 mg; cefazolin: 200 mg; clindamycin:
300 mg; vancomycin: 100–250 mg;
gentamicin: 40 mg).
N/A
Lawinski et al. (33), Poland 5 d. With or without systemic ABs. Day 1: 95% ethanol lock solution.Day 5:
sensitivity-guided solutions (100 mg
amikacin/mL; 40 mg teicoplanin/mL;
50 mg vancomycin/mL).
CVC removal
Messing et al. (37), France 14–27 d with dwell time of 12 h. Group
I ALT alone; Group II ALT with
systemic ABs: methicillin.
Sensitivity-guided solutions(S. epidermidis:
2 mg vancomycin/d; Corynebacterium
spp.: 0.4 mg minocycline/d; GNR and




Rijnders et al. (31), Belgium 7–14 d combined with systemic ABs
according to IDSA guidelines.
Ceftazidime for GNR and vancomycin for







Santarpia et al. (44), Italy Once or twice a day for >7 d.
Combination of 2 culture-guided
systemic ABs.
The same as the systemic AB with lowest
MIC, diluted with 1–2 mL heparinized
solution (500 IU/mL).
N/A
Santarpia et al. (45), Italy 14–28 d (median 21 d). Culture-guided
systemic ABs.
Teicoplanin (20), daptomycin (9), or
meropenem (4).
N/A
Vidal et al. (32), France 1–14 d (mean 7 d). Systemic ABs:
vancomycin and ceftazidime
(2 cases).
Vancomycin (11), amikacin (5), ethanol
(5), or ceftazidime (2).
N/A
1AB, antibiotic; ALT, antimicrobial lock therapy; CNS, coagulase-negative staphylococci; CVC, central venous catheter; GNR, Gram-negative rods;
GPC, Gram-positive cocci; IDSA, Infectious Diseases Society of America; MIC, minimum inhibitory concentration; N/A, not applicable.
infections despite catheter salvage. The majority of the included
case reports in this review related to cases with a complicated
course of CRBSI including recurrent CRBSIs and rare causative
pathogens. Also, the reported clinical outcomes differed widely.
Therefore, we decided not to combine these results in our meta-
analysis. Supplemental Tables 8 and 9 outline a summary of the
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FIGURE 2 Forest plots of proportion (95% CI) of successful catheter salvage per study. (A) Overall successful central venous catheter salvage proportions.
(B) Subanalysis per intervention type. The vertical lines represent the mean salvage proportion per intervention type, taking into account within-group variation.
Mixed-effects logistic regression analysis showed that the combination of systemic ABs with ALT was superior to systemic ABs alone (OR: 1.75; 95% CI:
1.21, 2.53; P = 0.003). AB, antibiotic; ALT, antimicrobial lock therapy.
Discussion
This systematic review describes and compares the efficacy
of 3 CRBSI management options for patients receiving HPN.
These data show that successful catheter salvage can be
achieved in the majority (68%) of HPN-dependent patients
with a CRBSI, when catheter removal is not indicated. More
importantly, the data indicate that ALT in addition to systemic
antibiotics is superior to systemic antibiotic treatment alone
for successful catheter salvage (OR: 1.75; 95% CI: 1.21, 2.53;
P = 0.003).
The benefit of ALT in tandem with systemic antibiotics has
previously been described in a systematic review and meta-
analysis in hemodialysis patients, which mainly comprised case-
control studies (61). In line with our findings, the authors
concluded that the addition of an antimicrobial lock solution is
superior to systemic antibiotics alone; however, lack of good-
quality clinical trials precluded firm conclusions from being
drawn. Likewise, the yield of randomized controlled clinical
trials in our systematic search was low, with only 1 RCT
included (31). Although a notable nonsignificant difference in
salvage success rates was observed between ALT and placebo
groups (57% compared with 33%; P = 0.10), this study was
underpowered and ceased prematurely because of slow patient
inclusion.
The IDSA guidelines for the diagnosis and management of
CRBSI give 2 recommendations regarding the use of ALT as
an adjunct therapy for catheter salvage: 1) it is advised that
ALT is used (evidence B-II); 2) it is recommended to attempt
catheter salvage in uncomplicated CRBSI involving long-term
catheters due to pathogens other than S. aureus, P. aeruginosa,
fungi, or mycobacteria, with the use of both systemic antibiotics
and ALT (B-II). These recommendations are in keeping with
our findings, because the lowest catheter salvage success rates
were found in CRBSIs caused by S. aureus. Nevertheless, the
addition of ALT still resulted in higher catheter salvage success
rates than systemic antibiotic treatment alone. Two studies
showed that successful salvage rates of >75% could be achieved
even in CRBSIs caused by S. aureus (16, 38). Caution may
be required, however, because several of the included studies
initially excluded catheter salvage in CRBSIs caused by S. aureus
because of published guidelines and CVC removal within 72 h
has been adopted as one of the key quality indicators for optimal
S. aureus bacteremia management in antibiotic stewardship
programs (62).
Only 1 study included in this meta-analysis used CVC
exchange via a guidewire as CRBSI treatment (34). We did find
2 other studies that applied CVC exchange in patients receiving
parenteral nutrition with our systematic search, but these only
involved hospitalized patients (63, 64). In our opinion, catheter
exchange via a guidewire is only indicated on the rare occasions
when a hemodynamically stable HPN patient with CRBSI cannot
be successfully treated with antimicrobial therapy and options to
obtain venous access are extremely limited.
Some of the studies included in our analysis also attempted
CVC salvage in patients with nontunneled and peripherally
inserted central catheters (PICCs) (35, 48). It remains debatable
as to whether CVC salvage for these devices is as appropriate
as for tunneled CVCs and implanted ports, because nontunneled
CVCs (including PICCs) themselves may carry a heightened risk
of CRBSI acquisition (65–67).
CRBSIs caused by yeasts or fungi were not the scope of this
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FIGURE 3 Forest plots of proportion of recurrence per study divided per intervention type. The vertical lines represent the mean successful salvage
proportion per intervention type, taking into account within-group variation. Mixed-effects logistic regression analysis showed that recurrence of infection
was less common in studies that used the combination of systemic ABs with ALT than in those that used systemic ABs alone (OR: 0.26; 95% CI: 0.11, 0.61;
P = 0.002) (CVC exchange group excluded). AB, antibiotic; ALT, antimicrobial lock therapy; CVC, central venous catheter.
infections by all major international guidelines (5, 12, 14, 68). In
addition, there are limited clinical data to support the effective-
ness of antifungal locks for patients with candidemia (69), and
the use of such locks is currently not standard practice (5, 12).
An important question that remains is the most effective
composition and dose of the antimicrobial lock solution. There
was wide variability in the reported concentrations and types
of administered locks between the studies of this systematic
review. Previous in vitro studies demonstrated that concentrations
of lock solutions need to be ≥5 mg/mL, whereas several of
the studies in this review used lower concentrations (15, 16,
36, 38, 42). It is also important to take reported dwell times
into consideration which, unfortunately, were not reported in
most of the included studies. Moreover, sufficient dwell time
may be difficult to achieve if the catheter is used for parenteral
nutrition infusion during the salvage protocol. Concerns also
exist relating to the emergence of multiresistant bacteria resul-
tant from antibiotic lock use, although data to support these
concerns are currently lacking (70). Finally, limitations on lock
availability between different countries may limit the choice
available.
A major strength of our systematic review is its strict adherence
to the PRISMA and MOOSE guidelines: the protocol was
prepublished (PROSPERO registry); an up-to-date and extensive
systematic literature search was performed; a structured risk of
bias assessment was undertaken by 2 independent authors using
the NOS, which is widely supported in observational research;
the complete data set was controlled for mistakes by a second
investigator; and case reports/series were excluded from the
meta-analysis to minimize selection bias.
There remain several limitations to the interpretation of our
findings. The most important limitation is that only 1 RCT
could be included (31). This finding in itself highlights the lack
of RCTs in evaluating CRBSI management in HPN-dependent
patients, despite these being the most serious complication for
this vulnerable group of patients. In addition, assessment of study
quality using the NOS tool showed that one-quarter of the studies
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FIGURE 4 Boxplots of successful CVC salvage rates divided by the
type of causative pathogen. (A) Overall CVC salvage rates. (B) CVC salvage
rates for studies using ALT in addition to systemic ABs. (C) CVC salvage
rates for systemic AB therapy–only studies. Circles denote outliers. ORs for
CVC salvage (all treatments): CNS compared with S. aureus: 3.00; 95% CI:
2.33, 3.85; P < 0.001; CNS compared with GNR: 2.19; 95% CI: 1.84, 2.60;
P < 0.001; GNR compared with S. aureus: 1.37; 95% CI: 1.07, 1.76; P = 0.01.
AB, antibiotic; ALT, antimicrobial lock therapy; CNS, coagulase-negative
staphylococci; CVC, central venous catheter; GNR, Gram-negative rods; S.
aureus, Staphylococcus aureus.
not affect our results based on regression meta-analysis. Strong
heterogeneity was present when pooling the successful salvage
rates of all intervention groups together. In the subanalysis
dividing studies per type of intervention, heterogeneity decreased
substantially, but moderate heterogeneity was still present in
the systemic antibiotic group. Another limitation was the wide
variation in reporting successful catheter salvage outcomes. As
outlined earlier, some studies only attempted salvage for CNS
infections, whereas others attempted salvage of all CRBSIs,
regardless of pathogen. Furthermore, in the absence of a
universally agreed-on definition of successful CVC salvage,
different approaches were used by different authors of the studies
included in this review. In our opinion, successful catheter
salvage is only achieved when all of the following criteria
are met: clinical resolution, negative blood cultures performed
≥48–72 h after antibiotic discontinuation (because of the long
half-lives of several of the frequently used antibiotics), and
no recurrence of infection with an identical strain for ≥2 mo.
TABLE 4 ORs of successful catheter salvage (antimicrobial lock therapy
combined with systemic ABs compared with systemic ABs alone) per type
of infecting pathogen1
Infecting pathogen OR (95% CI) P value
Staphylococcus aureus 2.00 (1.27, 3.13) 0.003
GNR 2.02 (1.05, 3.87) 0.035
CNS 1.14 (0.49, 2.67) 0.757
Polymicrobial 1.11 (0.50, 2.47) 0.804
1AB, antibiotic; CNS, coagulase-negative staphylococci; GNR,
Gram-negative rods.
Notably, only 2 studies fulfilled these criteria (40, 54). Although
several studies performed control blood cultures at the end of
antibiotic treatment, they only reported recurrence rates within
<30 d (15, 42, 46, 51). Furthermore, because different CRBSI
definitions were used by studies, we endeavored to limit the
impact of any potential misclassification bias by correcting
for studies that used nonstandard definitions. In recent years,
more ALT studies have been published and the approaches
adopted to CRBSI diagnosis and management have also changed
simultaneously in many centers; for example, there has been
a recent paradigm shift toward shorter antibiotic treatment
protocols for uncomplicated infections (71). These changes over
time could lead to chronological time bias, resulting in a potential
overestimation of the true benefit of the addition of ALT to
systemic antibiotics. Funnel plots of published ALT studies
showed no evident publication bias, but small studies were mainly
included, and the few larger studies tended to have lower salvage
rates. To overcome this issue, we weighted the analysis by study
size and performed sensitivity analysis by excluding small studies
of <10 patients. A final limitation of note is that some of the
included studies had a primary purpose other than the treatment
outcome of interest for this meta-analysis, which could have led
to a degree of reporting bias.
Despite the limitations outlined, this is the only meta-analysis
that we know of on CBRSI management and catheter salvage in
patients receiving HPN. Therefore, it is highly relevant to this
population, where catheter preservation is the ultimate treatment
goal. However, there is a clear need for additional high-quality
clinical trials comparing the treatment options and also evaluating
outcomes per pathogen. Additional topics that require well-
designed research are studies assessing the most effective and
safe ALT composition, as well as the optimal treatment duration
and dwell time.
We conclude that the addition of ALT to systemic antibiotic
treatment is associated with increased successful catheter salvage
rates compared with systemic antibiotic treatment alone for
CRBSI management in patients receiving HPN. Although most of
the included studies were retrospective cohort in design, limiting
the strength of our findings, it is important to recognize that
larger prospective multicenter studies will ultimately be difficult
to perform considering the rarity of this condition and the ethical
barriers to enrolling patients with a life-threatening infection
into a trial where they may not receive the best possible care.
Hence, there is a need for more pragmatic and innovative clinical
trials overcoming these issues, such as adopting an adaptive
trial design (72), in order to reliably evaluate the true benefit
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FIGURE 5 Funnel plots for examining publication bias. (A) Funnel plot of all the studies included for meta-analysis with SEs and salvage proportions. (B)
Visual funnel plot of salvage rates and study size with trend lines per intervention type. Egger’s regression test: ALT studies, P = 0.052; systemic AB studies,
P = 0.002. AB, antibiotic; ALT, antimicrobial lock therapy.
We appreciate the work of the investigators who published the studies
we have reviewed, with a special thanks to Darren R Linkin, University of
Pennsylvania, who also provided additional data and analyses upon request.
We thank Pim Lepelaars for his help with data visualization.
The authors’ responsibilities were as follows—MG and CP: conceptu-
alized the study, performed the investigation, and prepared and wrote the
original draft; MG, CP, CPB-R, GJAW, and RPA: outlined the methodology;
MG and RPA: conducted the statistical analysis; MG, CP, AB, SL, and GJAW:
performed the risk of bias assessment; MG: performed the visualization and
is the guarantor of the article; MG, CP, AB, CPB-R, SL, and GJAW: reviewed
and edited the original draft; and all authors: read and approved the final
manuscript. The authors report no conflicts of interest.
Data availability
The data used in the article that support the findings of
this study are available from the corresponding author upon
reasonable request.
References
1. Pironi L, Paganelli F, Labate AMM, Merli C, Guidetti C, Spinucci G,
Miglioli M. Safety and efficacy of home parenteral nutrition for chronic
intestinal failure: a 16-year experience at a single centre. Dig Liver Dis
2003;35(5):314–24.
2. Brandt CF, Tribler S, Hvistendahl M, Naimi RM, Brøbech P, Staun M,
Jeppesen PB. Home parenteral nutrition in adult patients with chronic
intestinal failure: catheter-related complications over 4 decades at the
main Danish tertiary referral center. JPEN J Parenter Enteral Nutr
2018;42(1):95–103.
3. Marra AR, Opilla M, Edmond MB, Kirby DF. Epidemiology of
bloodstream infections in patients receiving long-term total parenteral
nutrition. J Clin Gastroenterol 2007;41:19–28.
4. Gillanders L, Angstmann K, Ball P, O’Callaghan M, Thomson A, Wong
T, Thomas M. A prospective study of catheter-related complications in
HPN patients. Clin Nutr 2012;31(1):30–4.
5. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP,
Raad II, Rijnders BJA, Sherertz RJ, Warren DK. Clinical practice
guidelines for the diagnosis and management of intravascular catheter-
related infection: 2009 update by the Infectious Diseases Society of
America. Clin Infect Dis 2009;49(1):1–45.
6. O’Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard
SO, Lipsett PA, Masur H, Mermel LA, Pearson ML, et al. Summary
of recommendations: guidelines for the prevention of intravascular
catheter-related infections. Clin Infect Dis 2011;52(9):1087–99.
7. Bonnes SL, Mundi MS, Hurt RT, Salonen BR. To pull or not to pull:
salvaging central line catheters in home parenteral nutrition. Curr Nutr
Rep 2018;7:324–8.
8. Burnham JP, Rojek RP, Kollef MH. Catheter removal and outcomes
of multidrug-resistant central-line-associated bloodstream infection.
Medicine (Baltimore) 2018;97:e12782.
9. Lee Y-M, Moon C, Kim YJ, Lee HJ, Lee MS, Park K-H. Clinical impact
of delayed catheter removal for patients with central-venous-catheter-
related Gram-negative bacteraemia. J Hosp Infect 2018;99:106–13.
10. El Zakhem A, Chaftari AM, Bahu R, El Helou G, Shelburne S, Jiang
Y, Hachem R, Raad I. Central line-associated bloodstream infections
caused by Staphylococcus aureus in cancer patients: clinical outcome
and management. Ann Med 2014;46(3):163–8.
11. Fowler VG Jr, Justice A, Moore C, Benjamin DK Jr, Woods CW,
Campbell S, Reller LB, Corey GR, Day NP, Peacock SJ. Risk factors
for hematogenous complications of intravascular catheter–associated
Staphylococcus aureus bacteremia. Clin Infect Dis 2005;40(5):
695–703.
12. Pironi L, Arends J, Bozzetti F, Cuerda C, Gillanders L, Jeppesen PB,
Joly F, Kelly D, Lal S, Staun M, et al. ESPEN guidelines on chronic
intestinal failure in adults. Clin Nutr 2016;35(2):247–307. Erratum in:
Clin Nutr 2017;36(2):619.
13. Raad I, Hanna H, Maki D. Intravascular catheter-related infections:
advances in diagnosis, prevention, and management. Lancet Infect Dis
2007;7:645–57.
14. Liang S, Marschall J. Update on emerging infections: news from the
Centers for Disease Control and Prevention. Vital signs: central line–
associated blood stream infections—United States, 2001, 2008, and
2009. Ann Emerg Med 2011;58:447–51.
15. Dibb MJ, Abraham A, Chadwick PR, Shaffer JL, Teubner A, Carlson
GL, Lal S. Central venous catheter salvage in home parenteral nutrition
catheter-related bloodstream infections: long-term safety and efficacy
data. JPEN J Parenter Enteral Nutr 2016;40(5):699–704.
16. Bond A, Teubner A, Taylor M, Cawley C, Abraham A, Dibb M,
Chadwick PR, Soop M, Carlson G, Lal S. Assessing the impact
of quality improvement measures on catheter related blood stream
infections and catheter salvage: experience from a national intestinal
failure unit. Clin Nutr 2018;37(6 Pt A):2097–101.
17. Edakkanambeth Varayil J, Whitaker JA, Okano A, Carnell JJ, Davidson
JB, Enzler MJ, Kelly DG, Mundi MS, Hurt RT. Catheter salvage after
catheter-related bloodstream infection during home parenteral nutrition.
JPEN J Parenter Enteral Nutr 2017;41(3):481–8.
18. Aslam S, Vaida F, Ritter M, Mehta RL. Systematic review and meta-
analysis on management of hemodialysis catheter-related bacteremia. J
Am Soc Nephrol 2014;25:2927–41.
19. Kovacevich DS, Corrigan M, Ross VM, McKeever L, Hall AM,
Braunschweig C. American Society for Parenteral and Enteral Nutrition











trecht user on 26 O
ctober 2021
Review: catheter salvage for CRBSI in HPN patients 1187
adult home parenteral nutrition administration. JPEN J Parenter Enteral
Nutr 2019;43(1):15–31.
20. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA
statement. PLoS Med 2009;6:e1000097.
21. Bramer WM, de Jonge GB, Rethlefsen ML, Mast F, Kleijnen J. A
systematic approach to searching: an efficient and complete method to
develop literature searches. J Med Libr Assoc 2018;106:531–41.
22. Schoot RA, van Dalen EC, van Ommen CH, van de Wetering MD.
Antibiotic and other lock treatments for tunnelled central venous
catheter-related infections in children with cancer. Cochrane Database
Syst Rev 2013;(6):CD008975.
23. Zakhour R, Hachem R, Alawami HM, Jiang Y, Michael M, Chaftari
AM, Raad I. Comparing catheter-related bloodstream infections
in pediatric and adult cancer patients. Pediatr Blood Cancer
2017;64(10):26537.
24. Tribler S, Brandt CF, Fuglsang KA, Staun M, Broebech P, Moser
CE, Scheike T, Jeppesen PB. Catheter-related bloodstream infections
in patients with intestinal failure receiving home parenteral support:
risks related to a catheter-salvage strategy. Am J Clin Nutr 2018;107(5):
743–53.
25. Lee C-H, Su L-H, Chen F-J, Tang Y-F, Chien C-C, Liu J-W. Clinical and
microbiologic characteristics of adult patients with recurrent bacteremia
caused by extended-spectrum β-lactamase-producing Escherichia
coli or Klebsiella pneumoniae. Clin Microbiol Infect 2015;21:
1105.e1–8.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin
Trials 1986;7(3):177–88.
27. Deeks JJ, Higgins JPT, Altman DG. Analysing data and undertaking
meta-analyses [Internet]. In: Higgins JPT, Thomas J, Chandler J,
Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook
for systematic reviews of interventions version 6.1 (updated September
2020). Cochrane; 2019, 241–284. Available from: www.training.cochr
ane.org/handbook.
28. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-
analysis detected by a simple, graphical test. BMJ 1997;315(7109):
629–34.
29. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis
with R: a practical tutorial. Evid Based Ment Health 2019;22(4):
153–60.
30. Viechtbauer W. Conducting meta-analyses in R with the metafor
package. J Stat Soft 2010;36(3):1–48.
31. Rijnders BJ, Van Wijngaerden E, Vandecasteele SJ, Stas M, Peetermans
WE. Treatment of long-term intravascular catheter-related bacteraemia
with antibiotic lock: randomized, placebo-controlled trial. J Antimicrob
Chemother 2005;55(1):90–4.
32. Vidal M, Genillon JP, Forestier E, Trouiller S, Pereira B, Mrozek N,
Aumeran C, Lesens O. Outcome of totally implantable venous-access
port-related infections. Med Mal Infect 2016;46(1):32–8.
33. Lawinski M, Majewska K, Gradowski L, Foltyn I, Singer P.
A comparison of two methods of treatment for catheter-related
bloodstream infections in patients on home parenteral nutrition. Clin
Nutr 2015;34:918–22.
34. Ladefoged K, Efsen F, Krogh Christoffersen J, Jarnum S. Long-
term parenteral nutrition. II. Catheter-related complications. Scand J
Gastroenterol 1981;16(7):913–19.
35. Caroff DA, Norris AH, Keller S, Vinnard C, Zeitler KE, Lukaszewicz
J, Zborowski KA, Linkin DR; CDC Prevention Epicenters Program.
Catheter salvage in home infusion patients with central line–
associated bloodstream infection. Am J Infect Control 2014;42(12):
1331–3.
36. Fortún J, Grill F, Martín-Dávila P, Blázquez J, Tato M, Sánchez-
Corral J, García-San Miguel L, Moreno S. Treatment of long-term
intravascular catheter-related bacteraemia with antibiotic-lock therapy.
J Antimicrob Chemother 2006;58(4):816–21.
37. Messing B, Peitra-Cohen S, Debure A, Beliah M, Bernier JJ. Antibiotic-
lock technique: a new approach to optimal therapy for catheter-related
sepsis in home-parenteral nutrition patients. JPEN J Parenter Enteral
Nutr 1988;12(2):185–9.
38. Clare A, Teubner A, Shaffer JL. What information should lead to a
suspicion of catheter sepsis in HPN? Clin Nutr 2008;27(4):552–6.
39. Lorentsen R, Munck LK, Wildt S. Parenteral therapy and complications
in patients with intestinal failure in a regional unit. Scand J
Gastroenterol 2017;52(12):1326–30.
40. Krzywda EA, Andris DA, Edmiston CE Jr, Quebbeman EJ. Treatment
of Hickman catheter sepsis using antibiotic lock technique. Infect
Control Hosp Epidemiol 1995;16(10):596–8.
41. Haag GM, Berger AK, Jäger D. Treatment of long-term catheter-related
bloodstream infections with a taurolidine block: a single cancer center
experience. J Vasc Access 2011;12(3):244–7.
42. Fernandez-Hidalgo N, Almirante B, Calleja R, Ruiz I, Planes AM,
Rodriguez D, Pigrau C, Pahissa A. Antibiotic-lock therapy for
long-term intravascular catheter-related bacteraemia: results of an
open, non-comparative study. J Antimicrob Chemother 2006;57(6):
1172–80.
43. Guedon C, Nouvellon M, Lalaude O, Lerebours E. Efficacy of
antibiotic-lock technique with teicoplanin in staphylococcus
epidermidis catheter-related sepsis during long-term parenteral
nutrition. JPEN J Parenter Enteral Nutr 2002;26:109–13.
44. Santarpia L, Alfonsi L, Tiseo D, Creti R, Baldassarri L, Pasanisi F,
Contaldo F. Central venous catheter infections and antibiotic therapy
during long-term home parenteral nutrition: an 11-year follow-up study.
JPEN J Parenter Enteral Nutr 2010;34(3):254–62.
45. Santarpia L, Buonomo A, Pagano MC, Alfonsi L, Foggia M, Mottola
M, Marinosci GZ, Contaldo F, Pasanisi F. Central venous catheter
related bloodstream infections in adult patients on home parenteral
nutrition: prevalence, predictive factors, therapeutic outcome. Clin Nutr
2016;35(6):1394–8.
46. Benezra D, Kiehn TE, Gold JW, Brown AE, Turnbull AD, Armstrong
D. Prospective study of infections in indwelling central venous catheters
using quantitative blood cultures. Am J Med 1988;85:495–8.
47. Buchman AL, Moukarzel A, Goodson B, Herzog F, Pollack P, Reyen
L, Alvarez M, Ament ME, Gornbein J. Catheter-related infections
associated with home parenteral nutrition and predictive factors for the
need for catheter removal in their treatment. JPEN J Parenter Enteral
Nutr 1994;18(4):297–302. Erratum in: JPEN J Parenter Enteral Nutr
1997;21(2):117.
48. Rannem T, Ladefoged K, Tvede M, Lorentzen JE, Jarnum S. Catheter-
related septicaemia in patients receiving home parenteral nutrition.
Scand J Gastroenterol 1986;21(4):455–60.
49. O’Keefe SJ, Burnes JU, Thompson RL. Recurrent sepsis in home
parenteral nutrition patients: an analysis of risk factors. JPEN J Parenter
Enteral Nutr 1994;18(3):256–63.
50. Alonso B, Fernández-Cruz A, Díaz M, Sánchez-Carrillo C, Martín-
Rabadán P, Bouza E, Muñoz P, Guembe M. Can vancomycin lock
therapy extend the retention time of infected long-term catheters?
APMIS 2020;128(6):433–9.
51. Campo M, Moreno JM, Albiñana S, Valero MA, Gomis P, León-Sanz
M. Outpatient intravenous antibiotic therapy for catheter infections
in patients on home parenteral nutrition. Nutr Clin Pract 2001;16:
20–4.
52. Cuerda C, Camblor M, Breton I, Garcia-Peris P. Long-term follow-up
of home parenteral nutrition at a general hospital: complications and
quality of life. Nutr Hosp 2002;17:15–21(Spanish).
53. Leiberman D, Stevenson RP, Banu FW, Gerasimidis K, McKee RF. The
incidence and management of complications of venous access in home
parenteral nutrition (HPN): a 19 year longitudinal cohort series. Clin
Nutr ESPEN 2020;37:34–43.
54. Miller SJ, Dickerson RN, Graziani AA, Muscari EA, Mullen JL.
Antibiotic therapy of catheter infections in patients receiving home
parenteral nutrition. JPEN J Parenter Enteral Nutr 1990;14:143–7.
55. Thompson SG, Higgins JP. How should meta-regression analyses be
undertaken and interpreted? Stat Med 2002;21(11):1559–73.
56. Haneda S, Chikashi S, Miura K, Takeshi N, Watanabe K, Ohnuma S,
Sasaki H, Kakyo M, Morikawa T, Tanaka N, et al. Risk factors and
treatment for catheter-related blood stream infection in patients with
benign diseases undergoing home parenteral nutrition therapy. Eur Surg
Res 2013;50:85–6 (abstr).
57. Ohji G, Oba Y, Takimoto K, Kagawa H, Uchida D, Suganaga R, Oka H,
Kinoshita S, Nakamura M, Yoshida H, et al. Bacillus cereus bacteremia
in hospital setting. Int J Infect Dis 2010;14:e388 (abstr).
58. Zink M, Löffler C, Ulmer M, Angermeier S, Caca K, Schwella N.
Parenteral nutrition as a risk factor for port-infections in hemato-
oncological patients. Onkologie 2011;34:258 (abstr).
59. Udvarhelyi G, Biro I, Meszarosne TA, Straub E, Fejer C, Futo J, Topa
L, Sahin P. Treatment of home parenteral nutrition related catheter












trecht user on 26 O
ctober 2021
1188 Gompelman et al.
60. Ward SJ, Carlson GL, Anderson ID, Shaffer JL, Irving MH. How
effective is salvage of infected intravenous feeding catheters? Gut
1997;41:A14–A15 (abstr).
61. O’Horo JC, Silva GLM, Safdar N. Anti-infective locks for treatment of
central line-associated bloodstream infection: a systematic review and
meta-analysis. Am J Nephrol 2011;34:415–22.
62. Dunne CP, Ryan P, Connolly R, Dunne SS, Kaballo MA, Powell J,
Woulfe B, O’Connell NH, Gupta RK. Management of Staphylococcus
aureus bacteraemia (SAB) in the oncology patient: further evidence
supports prompt removal of central venous catheters and shorter
duration of intravenous antimicrobial therapy. J Infect Prev
2020;2:100037.
63. Bozzetti F, Terno G, Bonfanti G, Scarpa D, Scotti A, Ammatuna M,
Bonalumi MG. Prevention and treatment of central venous catheter
sepsis by exchange via a guidewire. A prospective controlled trial. Ann
Surg 1983;198(1):48–52.
64. Porter KA, Bistrian BR, Blackburn GL. Guidewire catheter exchange
with triple culture technique in the management of catheter sepsis. JPEN
J Parenter Enteral Nutr 1988;12(6):628–32.
65. Christensen LD, Holst M, Bech LF, Drustrup L, Nygaard L, Skallerup
A, Rasmussen HH, Vinter-Jensen L. Comparison of complications
associated with peripherally inserted central catheters and Hickman™
catheters in patients with intestinal failure receiving home parenteral
nutrition. Six-year follow up study. Clin Nutr 2016;35(4):912–17.
66. Wouters Y, Roosenboom B, Causevic E, Kievit W, Groenewoud H,
Wanten GJA. Clinical outcomes of home parenteral nutrition patients
using taurolidine as catheter lock: a long-term cohort study. Clin Nutr
2019;38(5):2210–18.
67. Reitzel RA, Rosenblatt J, Chaftari AM, Raad II. Epidemiology
of infectious and noninfectious catheter complications in patients
receiving home parenteral nutrition: a systematic review and meta-
analysis. JPEN J Parenter Enteral Nutr 2019;43(7):832–51.
68. Mirtallo J, Canada T, Johnson D, Kumpf V, Petersen C, Sacks G,
Seres D, Guenter P; Task Force for the Revision of Safe Practices
for Parenteral Nutrition. Safe practices for parenteral nutrition. JPEN J
Parenter Enteral Nutr 2004;28(6):S39–70. Erratum in: JPEN J Parenter
Enteral Nutr 2006;30(2):177.
69. Benoit JL, Carandang G, Sitrin M, Arnow PM. Intraluminal antibiotic
treatment of central venous catheter infections in patients receiving
parenteral nutrition at home. Clin Infect Dis 1995;21(5):1286–8.
70. Dixon JJ, Steele M, Makanjuola AD. Anti-microbial locks increase
the prevalence of Staphylococcus aureus and antibiotic-resistant
Enterobacter: observational retrospective cohort study. Nephrol Dial
Transplant 2012;27(9):3575–81.
71. Spellberg B, Rice LB. Duration of antibiotic therapy: shorter is better.
Ann Intern Med 2019;171(3):210–11.












trecht user on 26 O
ctober 2021
